PRA Health Sciences (PRAH) Tops Q2 EPS by 5c, Beats on Revenues; Offers FY Revenue Guidance Above Consensus

PRA Health Sciences (NASDAQ: PRAH) reported Q2 EPS of $0.79, $0.05 better than the analyst estimate of $0.74. Revenue for the quarter came in at $533.72 million versus the consensus estimate of $447.79 million.

• Net new business of $603.2 million; Net book-to-bill of 1.32
• $457.9 million of service revenue; 16.2% growth at actual foreign exchange rates and 16.5% constant currency growth
• GAAP Net Income per diluted share was $0.45 and GAAP Net Income was $29.5 million
• Adjusted Net Income per diluted share was $0.79 per share and Adjusted Net Income was $51.7 million
• Updating full year 2017 service revenue guidance to between $1.825 billion and $1.855 billion, GAAP net income per diluted share to between $2.17 and $2.26, and Adjusted Net Income per diluted share to between $3.11 and $3.20

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Avangrid (AGR) Tops Q1 EPS by 19c
• Enphase Energy (ENPH) Misses Q1 EPS by 7c, misses on guidance